Growth Hormone for Osteoporosis Pseudoglioma Syndrome
- Conditions
- Osteoporosis Pseudoglioma Syndrome
- Interventions
- Biological: Human recombinant growth hormone
- Registration Number
- NCT01614171
- Lead Sponsor
- University of Maryland, Baltimore
- Brief Summary
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.
- Detailed Description
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Osteoporosis pseudoglioma syndrome
- Age 4 years and above
- not on medication for osteoporosis
- pregnant
- Age under 4 yrs
- Active malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Growth hormone therapy Human recombinant growth hormone Growth hormone treatment for 6 months
- Primary Outcome Measures
Name Time Method Bone quality by pQCT 6 months By pQCT: periosteal circumference, cortical density, trabecular density, section modulus
- Secondary Outcome Measures
Name Time Method Body fat percent 6 months Percent body fat by DXA
Trial Locations
- Locations (1)
University of Maryland School of Medicine
🇺🇸Baltimore, Maryland, United States